List of Excipients in Branded Drug VIGABATRIN

Generic Drugs Containing VIGABATRIN

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	vigabatrin	0054-0652	HYPROMELLOSE 2910
Hikma Pharmaceuticals USA Inc	vigabatrin	0054-0652	MAGNESIUM STEARATE
Hikma Pharmaceuticals USA Inc	vigabatrin	0054-0652	MICROCRYSTALLINE CELLULOSE 101

What are the Most Frequently-Used Excipients in VIGABATRIN?

# Of NDCs	Excipient
10	CELLULOSE, MICROCRYSTALLINE
1	HYDROXYPROPYL METHYLCELLULOSE
8	HYPROMELLOSE 2910

Vigabatrin Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Vigabatrin has a limited excipient-led differentiation window because the principal U.S. product, Sabril, is supplied as 500 mg tablets and 500 mg powder packets for oral solution, with the powder product listed as containing no inactive ingredients. The strongest commercial opportunities are therefore in pediatric dose flexibility, palatability, dispersion, packaging, administration devices, stability, and regional formulation adaptation rather than in a conventional generic tablet excipient substitution.[1]

What is the current vigabatrin product and regulatory landscape?

Vigabatrin is an irreversible inhibitor of GABA transaminase used in the United States for refractory complex partial seizures and infantile spasms. The FDA-approved products are subject to strict ophthalmic monitoring because vigabatrin can cause permanent bilateral concentric visual-field loss.[1,2]

Product attribute	U.S. status
Active ingredient	Vigabatrin
Main therapeutic uses	Refractory complex partial seizures; infantile spasms
Branded product	Sabril
Tablet strength	500 mg
Oral-solution packet	500 mg powder
Administration	Tablets or solution prepared with water
Key safety restriction	Risk Evaluation and Mitigation Strategy, including vision monitoring
Pediatric relevance	High, particularly for infantile spasms
Generic pathway	Abbreviated New Drug Application, subject to product-specific requirements
Biosimilar exposure	None; vigabatrin is a small molecule

Sabril is distributed through a restricted program. Prescribers, pharmacies, and patients must comply with requirements related to enrollment, dispensing, counseling, and ophthalmologic monitoring.[2]

The key commercial implication is that any new formulation must preserve the controlled-use framework. A product that complicates dose measurement, administration records, or monitoring could face adoption resistance even if it improves taste or convenience.

What excipients are used in vigabatrin products?

The excipient profile differs materially between tablets and oral-solution powder.

Vigabatrin tablets

The Sabril tablet label identifies inactive ingredients used for tablet manufacture and coating. These generally support powder flow, compression, disintegration, lubrication, and film-coating performance.[1] Depending on the product and jurisdiction, tablet formulations may include excipients such as microcrystalline cellulose, povidone, crospovidone or sodium starch glycolate, magnesium stearate, silicon dioxide, and coating materials.

The commercial value of tablet excipient changes is limited. A conventional immediate-release tablet is relatively easy to replicate, and changes must still demonstrate pharmaceutical equivalence, dissolution performance, stability, and bioequivalence under the applicable ANDA pathway.

Vigabatrin powder for oral solution

The Sabril powder-for-solution product is supplied in 500 mg packets and is labeled as containing no inactive ingredients.[1] The packet is dissolved before administration. This design avoids many conventional liquid-formulation problems:

• no preservative system;
• no suspending agent;
• no sweetener or flavor system;
• no liquid microbial stability burden;
• no need to maintain a multidose bottle after opening;
• reduced risk of excipient intolerance in very young patients.

This creates a specific strategic constraint. Adding excipients may improve the patient experience but can also create new regulatory, stability, compatibility, and safety burdens without improving efficacy.

Which excipient strategies have the greatest commercial potential?

The strongest opportunities are those that improve administration without materially changing exposure or creating a new safety issue.

1. Taste-masking systems

Vigabatrin oral solution may be difficult for infants and caregivers because the active ingredient is administered in a relatively concentrated aqueous preparation. Taste masking could improve adherence, particularly in repeated pediatric dosing.

Potential systems include:

• low-dose sweeteners;
• fruit or neutral flavors;
• polymeric taste-masking agents;
• ion-exchange complexes;
• multiparticulate coatings;
• rapidly dispersible granules with a flavor layer.

The preferred strategy is a low-excipient, low-volume system that does not delay dissolution or alter absorption. Strong flavors may be unsuitable for infants, and sweetener selection must account for gastrointestinal tolerance, dental exposure, metabolic considerations, and regional pediatric requirements.

A taste-masked formulation is most commercially defensible when it is paired with a proprietary dose-measurement system or a protected granule architecture. Taste masking alone may be difficult to defend against competitive reformulation.

2. Dose-flexible pediatric granules

Infantile spasms are treated with weight-based dosing. A 500 mg packet can require repeated partial-packet measurement or preparation of a solution from a defined volume. A more flexible product could use:

• lower-strength sachets;
• multiparticulate granules;
• unit-dose sticks;
• calibrated oral-syringe delivery;
• reconstituted concentrations optimized for small doses.

Dose flexibility is likely more valuable than a minor tablet excipient improvement because infant dosing frequently requires individualized volumes. A lower-strength presentation could reduce preparation errors, but it would increase packaging, manufacturing, and inventory complexity.

The most attractive design is a unit-dose powder or granule product that permits accurate withdrawal of a prescribed volume after reconstitution. The formulation should minimize sedimentation and maintain concentration uniformity throughout the dosing period.

3. Improved dispersibility and suspension uniformity

Vigabatrin powder is dissolved before administration, so a true solution is preferable to a suspension. If a new formulation uses granules or coated particles, the dosage form should dissolve rapidly and completely in a small volume of water.

Useful excipient functions include:

• wetting;
• rapid disintegration;
• prevention of agglomeration;
• pH control;
• improved powder flow;
• protection from humidity.

The principal development target is not merely faster dispersion. It is dose uniformity after preparation, especially when a caregiver administers only part of the prepared volume.

4. Stability-enhancing packaging

Vigabatrin powder is exposed to moisture, oxygen, and temperature variation during manufacturing, storage, shipment, and home use. Moisture-protective packaging may produce more commercial value than an excipient change.

Potential approaches include:

• high-barrier foil sachets;
• child-resistant unit-dose packs;
• desiccant-integrated cartons;
• low-headspace packaging;
• tamper-evident dose packs;
• calendarized packaging for restricted-distribution programs.

Packaging may also support REMS compliance by integrating preparation instructions, administration records, and discard directions. These features could be protected through device, packaging, or human-factors intellectual property even where composition claims are weak.

5. Low-volume liquid formulations

A ready-to-use liquid could reduce caregiver preparation steps, but it would introduce a more difficult development program. The formulation would require control of:

• microbial growth;
• preservative exposure;
• chemical stability;
• container compatibility;
• dose uniformity;
• shipping conditions;
• in-use stability;
• palatability.

For a liquid product intended for infants, preservative-free single-dose packaging would likely be more attractive clinically but more expensive commercially. Multidose bottles may reduce cost while increasing dosing and contamination risks.

A liquid formulation may be valuable in markets where caregivers have limited access to purified water or where packet preparation is inconvenient. In the United States, the added regulatory burden may outweigh the convenience benefit unless the product demonstrates a clear adherence or medication-error advantage.

What formulation patents could protect a new vigabatrin product?

A new vigabatrin product would have the strongest patent prospects around a specific formulation architecture or administration system rather than the active ingredient itself.

Composition-of-matter protection

Vigabatrin is an established small molecule. New composition-of-matter claims on the active ingredient are not a practical commercial strategy.

Formulation claims

Potential claim categories include:

• defined particle-size distribution;
• taste-masked granules;
• a specific polymeric coating;
• pH-controlled solution systems;
• moisture-protected powder compositions;
• low-strength unit-dose formulations;
• formulations with improved dissolution or dose uniformity;
• preservative-free liquid systems;
• compositions stable under defined temperature and humidity conditions.

The patent must link the excipient selection to a measurable technical effect. Claims covering only routine excipient substitution are vulnerable to obviousness attacks, particularly for an old immediate-release drug.

Method-of-use claims

Method-of-use opportunities may focus on:

• improved administration in infants;
• reduced dosing errors;
• administration through enteral feeding tubes;
• use of a defined concentration for weight-based dosing;
• improved adherence from reduced preparation steps.

Method claims may be commercially useful but are harder to enforce against a generic product if the labeling does not expressly promote the patented use.

Device and packaging claims

Packaging and administration systems may offer stronger practical protection than excipient claims. Examples include:

• unit-dose packets with integrated dose preparation instructions;
• calibrated oral syringes;
• reconstitution vessels;
• child-resistant and tamper-evident packaging;
• systems that preserve concentration uniformity;
• adherence-monitoring packaging linked to restricted dispensing.

These claims can create a differentiated product even when the underlying powder composition is not patentable.

When does vigabatrin lose exclusivity and what is the Orange Book status?

Vigabatrin no longer has a meaningful new-molecule exclusivity position in the United States. Sabril was approved in 2009, and its orphan-drug exclusivity period has expired.[1,3]

The commercial exclusivity position should be assessed through the current FDA Orange Book and FDA approval databases because listed patents, pediatric exclusivity, and product-specific information can change. A historical patent expiration date should not be treated as proof of current market protection.

Exclusivity category	Vigabatrin position
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Expired
Pediatric exclusivity	No current six-month extension associated with the original launch period
Patent-based protection	Historical and product-specific; requires current Orange Book review
REMS-related protection	Regulatory control, not market exclusivity
Biosimilar protection	Not applicable

The absence of active statutory exclusivity does not remove commercial barriers. A generic applicant must still address bioequivalence, product quality, labeling, restricted distribution, and any listed patent certifications.

How do Paragraph IV challenges affect vigabatrin competition?

A Paragraph IV challenge could target any unexpired Orange Book-listed patent covering a formulation, method of use, or delivery system. The risk profile depends on the patent category.

Patent type	Likely competitive effect
Active-ingredient patent	Low practical relevance because vigabatrin is old
Tablet formulation patent	Potentially relevant to tablet-only entry
Oral-solution composition patent	Relevant if the generic uses a similar formulation
Method-of-use patent	May permit a carve-out if the protected indication can be omitted
Packaging or device patent	Could require a non-infringing administration system
Manufacturing patent	May create process risk without blocking a different manufacturing route

A Paragraph IV filing can trigger patent litigation and a 30-month stay of approval under the Hatch-Waxman framework if the brand sponsor files suit within the statutory period. The existence and status of any such litigation must be verified through current FDA records and federal court dockets.

A generic applicant can reduce risk by using the simplest possible powder composition, avoiding unnecessary excipients, selecting a distinct packet or device design, and evaluating whether an indication carve-out is legally and commercially feasible.

What generic launch scenarios exist for vigabatrin?

Scenario 1: Low-cost powder-for-solution generic

This is the most direct competitive model. The applicant matches the reference product's strength, route, dosage form, and preparation instructions while minimizing excipient complexity.

Commercial advantages include:

• lower formulation risk;
• simple raw-material sourcing;
• reduced stability burden;
• limited clinical differentiation requirements.

The disadvantage is weak pricing power. Multiple generic suppliers could compete primarily on contract access, distribution reliability, and reimbursement.

Scenario 2: Pediatric differentiated product

A sponsor could develop a lower-strength, taste-masked, dose-flexible product. The target customers would include pediatric neurologists, specialty pharmacies, hospitals, and caregivers.

The product could command a premium if it reduces preparation errors or improves treatment persistence. The sponsor would need evidence from human-factors studies, palatability assessments, dose-uniformity testing, and real-world use.

Scenario 3: Ready-to-use liquid

A liquid product could improve convenience but would face higher manufacturing and packaging costs. It may have value in hospital settings, home care, and international markets where packet reconstitution is less practical.

The main risks are preservative tolerance, in-use stability, microbial control, and difficulty supporting a premium price.

Scenario 4: Formulation and device licensing

A specialty pharmaceutical company could license a taste-masking technology, pediatric granule platform, or calibrated administration device to an established generic or specialty distributor. This structure would reduce the licensee's internal development burden while giving the technology owner access to regulated distribution channels.

How does vigabatrin compare with other pediatric antiseizure products?

Product characteristic	Vigabatrin	Liquid antiseizure competitors
Primary pediatric need	Weight-based dosing, especially infantile spasms	Varies by indication
Main formulation challenge	Accurate preparation and administration	Taste, preservative system, stability
Excipient sensitivity	High in infants and medically complex patients	Product-specific
Delivery opportunity	Powder, granules, liquid, syringe	Often established liquid or suspension
Safety-management burden	High due to visual-field toxicity	Varies
Commercial differentiation	Dose flexibility and adherence	Taste, convenience, dosing accuracy
Biosimilar risk	None	None for small molecules
Generic substitution pressure	High after exclusivity expiry	Product-specific

Vigabatrin's safety-monitoring requirement changes the value equation. A formulation that increases adherence but also increases dosing errors or complicates monitoring may not be favored by prescribers. Any commercial proposition should connect the excipient or device change to a measurable operational benefit.

What manufacturing and intellectual-property barriers matter most?

The principal manufacturing barriers are technical rather than chemical.

Powder handling

Vigabatrin powder must support consistent filling into unit-dose packets. Relevant attributes include flowability, bulk density, electrostatic behavior, segregation, and moisture uptake. Granulation may improve fill accuracy but can affect dissolution and content uniformity.

Moisture control

Moisture-sensitive formulations require controlled processing conditions, high-barrier packaging, and validated sealing. Packaging changes can affect stability claims and distribution cost.

Dose uniformity

A formulation intended for partial-dose administration must demonstrate uniformity after reconstitution. This is more demanding than simply showing content uniformity in the original packet.

Tube administration

Hospital and home-care use may involve nasogastric or gastrostomy tubes. A formulation that clumps, adheres to tubing, or requires excessive flushing may have limited practical value. Tube compatibility should be tested with representative devices and preparation volumes.

Supply-chain resilience

Excipients should have multiple qualified suppliers, established pharmaceutical grades, and low risk of regional regulatory restrictions. A differentiated formulation that depends on a single specialty polymer can create avoidable supply exposure.

What is the best commercial excipient strategy for vigabatrin?

The most defensible strategy is a pediatric, unit-dose powder or granule platform with the following characteristics:

1. No unnecessary excipients in the baseline product.
2. Rapid dissolution in a small, defined water volume.
3. Accurate partial-dose withdrawal using a calibrated syringe.
4. Optional mild taste masking with low pediatric exposure.
5. High-barrier, single-use packaging.
6. Clear compatibility with enteral administration.
7. Human-factors evidence showing fewer preparation errors.
8. Patent claims directed to the composition, packaging, device, or combined system.

A conventional tablet excipient change has lower commercial potential. A ready-to-use liquid has higher patient convenience but also higher formulation and manufacturing risk. The best balance is likely a differentiated pediatric presentation that improves dosing accuracy without converting vigabatrin into a complex multidose liquid.

What revenue exposure and market opportunities exist?

Public disclosures generally do not provide a clean, standalone current revenue figure for vigabatrin across all markets and formulations. Market value is concentrated in a specialty population with high clinical need but limited volume. The commercial opportunity is therefore more likely to come from premium differentiation and specialty distribution than from large-scale primary-care volume.

The main revenue pools are:

• U.S. generic supply;
• branded or authorized-generic replacement;
• pediatric specialty formulations;
• hospital and institutional supply;
• international markets lacking convenient powder presentations;
• licensing of pediatric delivery technology;
• contract manufacturing of unit-dose packets or granules.

A sponsor should model revenue against three variables: the number of treated patients, net price after specialty-pharmacy discounts, and the degree of substitution by low-cost generics. A differentiated product must show that its adherence, dosing, or caregiver benefits support reimbursement beyond the price of a standard generic packet.

Key Takeaways

• Vigabatrin's active ingredient and core market exclusivity are mature.
• The U.S. powder-for-solution product is labeled without inactive ingredients, limiting the value of routine excipient substitution.
• Pediatric dose flexibility is the leading commercial opportunity.
• Taste masking, rapid dissolution, dose uniformity, and administration-device integration are stronger targets than tablet reformulation.
• Moisture-protective unit-dose packaging can create practical and potentially patentable differentiation.
• A ready-to-use liquid may improve convenience but creates substantial stability, microbial, and packaging burdens.
• Patent value is most likely to arise from a defined formulation system, device, packaging configuration, or human-factors solution.
• REMS and ophthalmic monitoring requirements must be incorporated into product design and commercialization.
• The best launch model is a specialty pediatric product that reduces preparation and dosing errors while preserving simple manufacturing.

FAQs About Vigabatrin Excipients and Commercialization

Can vigabatrin be formulated as a liquid suspension?

Yes, but a true solution is generally preferable. A suspension would require control of sedimentation, redispersibility, concentration uniformity, and dosing accuracy.

Is a preservative-free vigabatrin liquid commercially feasible?

Yes, most plausibly in single-dose containers. A multidose preservative-free product would face greater microbial and in-use stability challenges.

Can a generic company change the excipients in vigabatrin tablets?

Yes, subject to FDA product-specific requirements, pharmaceutical equivalence, bioequivalence, quality testing, and applicable patent certifications.

What excipient is best for masking vigabatrin taste?

No single excipient is universally optimal. The selection should be based on palatability, pediatric safety, dissolution, stability, and the final dose volume.

Does vigabatrin have biosimilar competition?

No. Vigabatrin is a chemically synthesized small molecule, so competition proceeds through generic drug pathways rather than biosimilar approval.

References

1. U.S. Food and Drug Administration. (2024). Sabril (vigabatrin) prescribing information.
2. U.S. Food and Drug Administration. (2024). Sabril Risk Evaluation and Mitigation Strategy.
3. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.
4. U.S. Food and Drug Administration. (2024). Vigabatrin product-specific guidance for industry.
5. National Library of Medicine. (2025). DailyMed: Vigabatrin prescribing information and product labeling.